Ani Pharmaceuticals Inc.

ANIP Nasdaq SEC CIK 1023024
Follow Ani Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $290.8M +27.6% vs same quarter last year
Net income $35.1M +32.1% vs same quarter last year
EPS, diluted $1.51 +33.6% vs same quarter last year
Operating cash flow $83.8M +90.2% vs same quarter last year
Revenue by quarter
$190.6M
$197.1M
$211.4M
$227.8M
$247.1M
$237.5M
$266M
$290.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$250M$0$250M$500M$750M$1BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$883.4M$78M
FY24$614.4M−$19M
FY23$486.8M$19M
FY22$316.4M−$48M
FY21$216.1M−$43M
FY20$208.5M−$22.5M
FY19$206.5M$6.1M
FY18$201.6M$15.5M
FY17$176.8M−$1.1M
FY16$128.6M$3.9M
FY15$76.3M$15.4M
FY14$56M$28.7M
FY13$30.1M$301K
FY12$20.4M−$1.5M
FY11$435.2K−$51.6M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−15000%−10000%−5000%0%5000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25-12.6%8.8%
FY24-0.1%−3.1%
FY23-9.6%3.9%
FY22-−11.2%−15.2%
FY21-−18.4%−19.9%
FY2058.2%−7.7%−10.8%
FY1969.4%7.9%3%
FY1863.8%17.5%7.7%
FY1755.3%16%−0.6%
FY1662.1%15.6%3.1%
FY1583.4%42.8%20.1%
FY1479.5%35.7%51.4%
FY1366.8%3%1%
FY1255%−0.2%−7.4%
FY11--−11859.7%
Free cash flowOperating cash flow minus capital expenditure
−$100M$0$100M$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$171.4M
FY24$47.8M
FY23$110.1M
FY22−$40.1M
FY21$765K
FY20$9.1M
FY19$39M
FY18$61.3M
FY17$29.1M
FY16$22.9M
FY15$15.1M
FY14$20.9M
FY13−$5.7M
FY12−$429K
FY11−$48.6M
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
$0$5M$10M$15MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearDividendsBuybacks
FY25$1.2M$12.2M
FY24$1.6M$11M
FY23$1.6M$5M
FY22$1.6M$2M
FY21$190K$890K
FY20$0$1.5M
FY19$0$1M
FY18-$0
FY17-$0
FY16-$2.5M
FY15-$0
FY14-$0
FY13-$433K
FY12-$0
FY11--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Ani Pharmaceuticals
  • Healthcare median
−15000%−10000%−5000%0%5000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearAni PharmaceuticalsHealthcare median
FY258.8%−30.6%
FY24−3.1%−47%
FY233.9%−58%
FY22−15.2%−80.4%
FY21−19.9%−71.9%
FY20−10.8%−62.2%
FY193%−46.3%
FY187.7%−49.6%
FY17−0.6%−45.9%
FY163.1%−36%
FY1520.1%−38.4%
FY1451.4%−35.5%
FY131%−37.1%
FY12−7.4%−29.1%
FY11−11859.7%−27.9%